Page 9 - Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

CUAJ – Consensus Statement Mason et al
KCRNC consensus: Cytoreductive nephrectomy for mRCC

loss, and shorter length of hospital stay[62-67]. Indeed, there is no reason that CN should
be approached differently than radical nephrectomy in patients without metastatic
disease. Overall, the surgical approach should be decided taking into consideration
patient and tumor characteristics, experience of the surgeon, and the potential need for
ancillary procedures (e.g. regional lymph node dissection, resection of surrounding
organs, and/or venous thrombectomy). Adrenal sparing, when there is no evidence of
tumor invasion or metastatic spread and when technically feasible, is appropriate.

Conclusion
CN remains an important component in the multimodal treatment of patients with mRCC.
The objective of this consensus statement is to aid Canadian clinicians in the appropriate
application of CN, based on currently available evidence, in order to improve the care of
patients with mRCC. The management of advanced kidney cancer is rapidly evolving,
and it will not be feasible to reevaluate the role of CN with the introduction of each new
incremental improvement in systemic therapy. We provide these recommendations until
new high-quality and relevant evidence becomes available, at which point this consensus
statement will be updated.